Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Jason R. Westin(The University of Texas MD Anderson Cancer Center), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Matthew L. Ulrickson, Christina To(Aadi (United States)), Frederick L. Locke(Moffitt Cancer Center), Julia Thornton Snider(Aadi (United States)), Gerald Wulf(University of Göttingen), Marie José Kersten(Hovon), Simone Filosto(Kite (United States)), Caron A. Jacobson(Dana-Farber Cancer Institute), John M. Pagel(University of Washington), Olalekan O. Oluwole(Vanderbilt University), Tom van Meerten(University Medical Center Groningen), Paul Cheng(VA San Diego Healthcare System), Jina Shah(University of Maryland, Baltimore), Luciano Wannesson(Università della Svizzera italiana), Saran Vardhanabhuti, Patrick B. Johnston(Mayo Clinic in Arizona), Linqiu Du(Aadi (United States)), Aaron P. Rapoport(University of Maryland, Baltimore), David B. Miklos(Stanford University), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Armin Ghobadi(Washington University in St. Louis), Umar Farooq(Wake Forest University), Mahmoud Elsawy(Dalhousie University), Michael Dickinson(The University of Melbourne), Lori A. Leslie(Hackensack University Medical Center)
Cited by 51
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k